Please login to the form below

Not currently logged in
Email:
Password:

lorlatinib

This page shows the latest lorlatinib news and features for those working in and with pharma, biotech and healthcare.

NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance

NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance

Lorviqua (lorlatinib) has meanwhile been recommended by NICE in final guidance as an option for treating patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed after

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics